Three (DCN, VEGF, and IL8) out of the 10 markers were significantly different (p-value < 0.05) in expression of protein levels concerning recurrent and non-recurrent BCa and were therefore considered highly suitable for detection of bladder cancer recurrence and therapy monitoring. This evidence concerns the gene CXCL8 and urinary bladder carcinoma.